In this intro and overview of Skye's Anatomy of Progress video series, we highlight Skye’s positioning and progress in obesity therapeutic drug development, noting the differentiation of its allosteric modulating antibody that takes into consideration fat metabolism, safety and long-term care.
A review of Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.
A review of Skye’s current clinical activity and near-term path to Phase 2a data.
Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with the target product profile of a peripherally-restricted CB1 inhibitor such as nimacimab.
Hosted by Evercore healthcare equity research analysts, Skye executives join with notable obesity physicians to discuss the CB1 pathway, nimacimab’s peripheral CB1 blockade, and the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era.
Skye’s poster presentation at the American Diabetes Association medical conference highlights nimacimab’s ability to achieve weight reduction and deliver comprehensive metabolic improvements including enhanced body composition, restoration of metabolic homeostasis, and improved hormonal profiles.
Presentation at this notable obesity-related medical conference reviewed nimacimab’s differentiated characteristics, reiterated meaningful weight loss data from a pre-clinical diet-induced obesity model, and introduced new biomarker data showing important reductions in obesity-induced inflammation and liver steatosis.
At ECO 2025, Skye presented its poster: “Demonstrating the sufficiency of peripheral CB1 inhibition to promote weight loss using clinical pharmacokinetic and pharmacodynamic models”
As part of the 2025 proxy package, this letter reviews what Skye has accomplished, why CB1 matters, and how we intend to move forward.
Skye CEO Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD, chat about the SXSW forum and weight loss in anticipation of the panel they participate in the following day, “Weighing in on Weight Loss.”